GI-6301
Phase 1- Indications
- Chordoma, Brachyury-expressing cancers
Company intelligence / Profile preview
GlobeImmune
Louisville, Colorado, United Statesglobeimmune.com ↗
- Ownership
- Public · GBIM
- Employees
- ~22
- Development stage
- Phase 2
01
Overview
The company has two Tarmogen product candidates in clinical evaluation for infectious disease and multiple cancer indications. GI-6207 and GI-6301 are in clinical trials for various cancers. A hepatitis B product candidate failed clinical trials in 2015.
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- Therapeutic vaccines (Tarmogens)
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
Celgene (established in 2009)National Cancer InstituteGilead (terminated in November 2016)
04
Financials
- Market cap
- $575
- Total revenue
- $6.5M
- Enterprise value
- $-8.7M
Beyond the preview
Go deeper on GlobeImmune.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GlobeImmune.